Donepezil is a centrally acting acetylcholinesterase inhibitor used in the management of Alzheimer’s disease. It improves cognitive function by increasing the levels of acetylcholine in the brain. Donepezil is effective in treating mild, moderate, and severe stages of Alzheimer’s disease. The drug helps enhance memory, attention, and daily functioning in affected patients. It is administered orally and is suitable for long-term therapy. Donepezil was developed to provide symptomatic relief rather than a cure for dementia. It has a favorable safety and tolerability profile compared to earlier treatments. The medication is widely prescribed due to its once-daily dosing convenience. Donepezil does not alter disease progression but slows cognitive decline. Today, it remains a cornerstone therapy in Alzheimer’s disease management.
